CFO Busky’s Latest Share Buy Signals Confidence Amid QuidelOrtho’s Volatile Turnaround Effort

Insider Buying by CFO Busky Joseph M. Signals Confidence Amid a Volatile Cycle

QuidelOrtho Corp’s chief financial officer, Joseph M. Busky, closed a 3,370‑share purchase on February 13, 2026, paying an average of $23.66 per share. The transaction raises the CFO’s stake to 10,290 shares—about 0.66 % of the outstanding equity—at a price only 0.02 % below the market close. In a sector that has seen a 41.65 % yearly decline and a negative P/E, the move is noteworthy. While the company’s stock has trended lower this year, the CFO’s buying coincides with a recent 11 % uptick in social‑media buzz and a +10 sentiment score, suggesting that investors are paying attention to insider activity as a potential harbinger of upside.

What This Means for Investors and the Company’s Outlook

The CFO’s purchase comes as QuidelOrtho navigates a challenging earnings cycle. The firm’s market cap of $1.57 billion and its 52‑week low of $19.50 are still far below the February high of $42.21, indicating significant upside potential if the company can execute its expansion plans. The long‑term partnership with Lifotronic Technology and the upcoming presentation at the Raymond James conference underscore a strategic pivot toward high‑performance immunoassays and point‑of‑care diagnostics. By taking a larger personal stake, Busky signals confidence that these initiatives will translate into revenue growth and share price appreciation, thereby bolstering shareholder value.

Busky Joseph M.: A Track Record of Strategic Buying

Historically, Busky has been an active insider buyer. In early February alone, he purchased 8,425 shares at $27.41 and 5,968 shares at $29.10, before selling 2,602 shares at the same price. Earlier in the year, he acquired 4,925 shares in March 2025 at $34.89 and added 8,425 shares in January 2025. Across the past 12 months, his purchases have averaged in the $23‑$30 range, reflecting a willingness to invest when valuations are attractive. While Busky has also sold shares—most notably 1,806 shares on February 8 at $29.10—his net position has steadily increased, suggesting a long‑term view rather than a short‑term trade.

Investor Takeaway

For portfolio managers and individual investors, Busky’s latest purchase may serve as a bellwether. It demonstrates that the CFO believes the company’s current valuation offers a buying opportunity, even as the stock remains depressed. Coupled with strategic supply‑chain expansions and a focus on high‑margin diagnostics, this insider confidence could presage a rebound. As always, investors should monitor subsequent insider transactions and company earnings releases to confirm whether the CFO’s optimism materializes into tangible upside.